Stocks · News reference
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415
Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $418 to $420.
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445
BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript
BeiGene (NASDAQ:ONC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and